MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$14,038K
EPS
-$0.26
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development expenses
11,535
6,995
13,587*
9,730
General and administrative expenses
4,283
4,718
3,914*
4,604
Total operating expenses
15,818
11,713
17,500
14,334
Loss from operations
-15,818
-11,713
-17,500*
-14,334
Interest income and other, net
1,865
1,063
1,404
1,426
Total other income
1,865
1,063
1,404*
1,426
Net loss
-13,953
-10,650
-16,097*
-12,908
Net unrealized loss on marketable securities
-85
-112
-104*
41
Total comprehensive loss
-14,038
-10,762
-16,201
-12,867
Basic EPS
-0.26
-0.33
-0.5
-0.4
Diluted EPS
-0.26
-0.33
-0.5
-0.4
Basic Average Shares
53,114,533
32,559,704
32,376,316
32,464,893
Diluted Average Shares
53,114,533
32,559,704
32,376,316
32,464,893
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$14,038K
(-34.58%↓ Y/Y)
Interest income and
other, net
$1,865K
(21.18%↑ Y/Y)
Net loss
-$13,953K
(-34.34%↓ Y/Y)
Net unrealized loss
on marketable...
-$85K
(-88.89%↓ Y/Y)
Total other income
$1,865K
(21.18%↑ Y/Y)
Loss from operations
-$15,818K
(-32.65%↓ Y/Y)
Total operating
expenses
$15,818K
(32.65%↑ Y/Y)
Research and development
expenses
$11,535K
(59.15%↑ Y/Y)
General and
administrative expenses
$4,283K
(-8.42%↓ Y/Y)
Buy us a coffee
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)